ReviewMedicine2026
Recurrent intracranial hemorrhage secondary to congenital factor XIII deficiency: A case report and literature review.
Review in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleCoagulation factor deficiencies can lead to hemorrhagic syndromes of varying severity and bleeding manifestations. Intracranial hemorrhage (ICH) associated with coagulation factor XIII (FXIII) deficiency is particularly challenging because its clinical presentation closely mimics spontaneous ICH, often occurring without apparent triggers. Routine coagulation tests (prothrombin time and activated partial thromboplastin time) are typically normal, contributing to diagnostic difficulties and frequent underdiagnosis or misclassification. As the management of this condition differs from other ICH types, replacement therapy with cryoprecipitate or fresh frozen plasma is crucial beyond surgical intervention. This case report highlights this rare, life-threatening condition to enhance clinical recognition. PATIENT CONCERNS: A 53-year-old Chinese male presented with recurrent ICH over a 20-day period and underwent 2 intracerebral hematoma evacuation surgeries. Postoperative head computed tomography (CT) revealed persistent rebleeding at the site of original hemorrhage. DIAGNOSES: Congenital FXIII deficiency, intracerebral hemorrhage, and cerebral herniation.
interventionsThe patient underwent surgical hematoma evacuation followed by allogeneic blood transfusion therapy, and received 10 units of cryoprecipitate daily. OUTCOMES: After 35 days of treatment, the patient regained full consciousness with normal cognitive and neurological responsiveness. Follow-up CT imaging revealed significant resolution of the hematoma. He was discharged in stable condition. Post-discharge management included weekly infusions of 6 to 10 units of cryoprecipitate at local medical facilities along with routine monitoring of coagulation profiles and cranial CT scans. LESSONS: Intracranial hemorrhage secondary to FXIII deficiency is exceedingly rare. Clinicians should consider FXIII deficiency when recurrent ICH occurs with normal routine coagulation tests, to enable early diagnosis and life-saving replacement therapy. Early identification of the underlying etiology through comprehensive diagnostic evaluation is essential to guide effective and timely interventions, particularly in the context of increasing ICH incidence and healthcare resource utilization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.